Pharmacological inhibition of tyrosine protein-kinase 2 reduces islet inflammation and delays type 1 diabetes onset in miceResearch in context

Summary: Background: Tyrosine protein-kinase 2 (TYK2) mediates inflammatory signalling through multiple cytokines, including interferon-α (IFNα), interleukin (IL)-12, and IL-23. TYK2 missense mutations protect against type 1 diabetes (T1D), and inhibition of TYK2 shows promise in other autoimmune c...

Full description

Saved in:
Bibliographic Details
Main Authors: Farooq Syed, Olivia Ballew, Chih-Chun Lee, Jyoti Rana, Preethi Krishnan, Angela Castela, Staci A. Weaver, Namratha Shivani Chalasani, Sofia F. Thomaidou, Stephane Demine, Garrick Chang, Alexandra Coomans de Brachène, Maria Ines Alvelos, Eugenia Martin Vazquez, Lorella Marselli, Kara Orr, Jamie L. Felton, Jing Liu, John S. Kaddis, Piero Marchetti, Arnaud Zaldumbide, Donalyn Scheuner, Decio L. Eizirik, Carmella Evans-Molina
Format: Article
Language:English
Published: Elsevier 2025-07-01
Series:EBioMedicine
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2352396425001781
Tags: Add Tag
No Tags, Be the first to tag this record!